Neuren Pharmaceuticals Limited Stock Current Valuation
| NURPF Stock | USD 12.53 0.00 0.00% |
Valuation analysis of Neuren Pharmaceuticals helps investors to measure Neuren Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Neuren Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Neuren Pharmaceuticals is based on 3 months time horizon. Increasing Neuren Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Neuren Pharmaceuticals Limited is useful when determining the fair value of the Neuren pink sheet, which is usually determined by what a typical buyer is willing to pay for full or partial control of Neuren Pharmaceuticals. Since Neuren Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Neuren Pink Sheet. However, Neuren Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 12.53 | Real 10.53 | Hype 12.53 |
The real value of Neuren Pink Sheet, also known as its intrinsic value, is the underlying worth of Neuren Pharmaceuticals Company, which is reflected in its stock price. It is based on Neuren Pharmaceuticals' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Neuren Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Neuren Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Neuren Pharmaceuticals Limited helps investors to forecast how Neuren pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Neuren Pharmaceuticals more accurately as focusing exclusively on Neuren Pharmaceuticals' fundamentals will not take into account other important factors: Neuren Pharmaceuticals Limited Company Current Valuation Analysis
Neuren Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Neuren Pharmaceuticals Current Valuation | 602.02 M |
Most of Neuren Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neuren Pharmaceuticals Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Neuren Pharmaceuticals Limited has a Current Valuation of 602.02 M. This is 95.81% lower than that of the Healthcare sector and 87.04% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 96.38% higher than that of the company.
Neuren Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neuren Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Neuren Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Neuren Pharmaceuticals by comparing valuation metrics of similar companies.Neuren Pharmaceuticals is currently under evaluation in current valuation category among related companies.
Neuren Fundamentals
| Return On Equity | -0.27 | |||
| Return On Asset | -0.17 | |||
| Profit Margin | (2.15) % | |||
| Operating Margin | (2.31) % | |||
| Current Valuation | 602.02 M | |||
| Shares Outstanding | 128.97 M | |||
| Shares Owned By Insiders | 16.48 % | |||
| Shares Owned By Institutions | 9.41 % | |||
| Price To Earning | 49.75 X | |||
| Price To Book | 27.96 X | |||
| Price To Sales | 203.95 X | |||
| Revenue | 3.2 M | |||
| Gross Profit | (6.32 M) | |||
| EBITDA | (11.43 M) | |||
| Net Income | (7.79 M) | |||
| Cash And Equivalents | 31.09 M | |||
| Cash Per Share | 0.25 X | |||
| Current Ratio | 31.54 X | |||
| Book Value Per Share | 0.27 X | |||
| Cash Flow From Operations | (9.97 M) | |||
| Earnings Per Share | (0.05) X | |||
| Number Of Employees | 15 | |||
| Beta | 1.5 | |||
| Market Capitalization | 660.11 M | |||
| Total Asset | 40.06 M | |||
| Retained Earnings | (97 M) | |||
| Working Capital | 7 M | |||
| Current Asset | 9 M | |||
| Current Liabilities | 2 M | |||
| Z Score | -2.8 | |||
| Net Asset | 40.06 M |
About Neuren Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neuren Pharmaceuticals Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neuren Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neuren Pharmaceuticals Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuren Pharmaceuticals Limited. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Neuren Pink Sheet analysis
When running Neuren Pharmaceuticals' price analysis, check to measure Neuren Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuren Pharmaceuticals is operating at the current time. Most of Neuren Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Neuren Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuren Pharmaceuticals' price. Additionally, you may evaluate how the addition of Neuren Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |